SCHEMBL9942918

SCHEMBL9942918

Cc1cc(CNC(=O)c2nc3n(c(=O)c2O)CC2(F)CCC3(NC(=O)c3cc(C(=O)N(C)C)on3)CC2)ccc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 8/20 0.37
CYP2C9 P11712 2/20 0.36
KCNH2 Q12809 1/20 0.36
MMP10 P09238 3/20 0.32
MMP8 P22894 3/20 0.32
MMP9 P14780 1/20 0.32
KCNE1 P15382 1/20 0.31
CCR1 P32246 1/20 0.31
KCNQ1 P51787 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
TP53 P04637 1/20 0.31
CYP1A2 P05177 1/20 0.31
POLB P06746 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C19 P33261 1/20 0.31
HTT P42858 1/20 0.31
CASP7 P55210 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9905205 0.91 MMP13 (0.39) MMP13CYP2C9KCNH2MMP10MMP8
SCHEMBL9901256 0.87 CYP2C9 (0.42) MMP13CYP2C9KCNH2MMP10MMP8
SCHEMBL9904898 0.84 MMP13 (0.38) MMP13CYP2C9KCNH2MMP10MMP8
SCHEMBL9901738 0.83 KCNH2 (0.37) MMP13CYP2C9KCNH2MMP10MMP8
SCHEMBL14212571 0.82 KCNH2 (0.37) MMP13CYP2C9KCNH2MMP10MMP8
SCHEMBL9904901 0.82 MMP13 (0.37) MMP13CYP2C9KCNH2MMP10MMP8
SCHEMBL9902391 0.82 CYP2C9 (0.36) MMP13CYP2C9KCNH2MMP10MMP8
SCHEMBL9904944 0.82 MMP13 (0.39) MMP13CYP2C9KCNH2MMP10MMP8
SCHEMBL9942985 0.81 HCRTR1 (0.40) MMP13S1PR3HPGD
SCHEMBL9901236 0.81 CYP2C9 (0.36) MMP13CYP2C9KCNH2MMP10MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835411-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-16 US disclosed
US-8835411-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-16 US disclosed
US-20120309698-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 US disclosed
US-20120309698-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 US disclosed
WO-2012078834-A1 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309698-A1 HIV Integrase Inhibitors DNTT, POLB, UNG MMP13 4137/4885CYP2C9 602/4885KCNH2 3969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.